|1.||Rucavado, Alexandra: 4 articles (07/2012 - 04/2002)|
|2.||Gutiérrez, José María: 4 articles (07/2012 - 04/2002)|
|3.||Escalante, Teresa: 3 articles (10/2008 - 04/2002)|
|4.||Khalil, Raouf A: 2 articles (03/2013 - 01/2008)|
|5.||Keck, Tobias: 2 articles (02/2009 - 01/2002)|
|6.||Wielockx, B: 2 articles (04/2007 - 11/2001)|
|7.||Libert, C: 2 articles (04/2007 - 11/2001)|
|8.||Krell, Hans-Willi: 2 articles (06/2004 - 03/2004)|
|9.||Lo, Eng H: 2 articles (01/2004 - 03/2002)|
|10.||Lü, H: 2 articles (12/2001 - 01/2000)|
04/01/2007 - "However, systemic treatment of tumor-bearing mice with TNF/IFNgamma in combination with BB-94 (a broad-spectrum metalloproteinase inhibitor) confers protection against TNF/IFNgamma-induced mortality, whereas preserving the antitumor activity. "
01/01/2014 - "The in vivo studies demonstrated that batimastat could suppress the growth of the subcutaneous tumors formed by the SCLs. "
01/01/2002 - "In this study, we investigated the effect of the matrix metalloproteinase inhibitor batimastat on the lung colonisation of orthotopically implanted malignant pancreatic tumor cells in SCID mice. "
01/01/1999 - "The purpose of this study was to determine MMP-2 and MMP-9 activity in orthotopic tumors from mice treated with and without BB-94. "
01/01/1996 - "Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer."
|2.||Wounds and Injuries (Trauma)
12/15/2015 - "Protective effects of batimastat against hemorrhagic injuries in delayed jellyfish envenomation syndrome models."
12/15/2015 - "Although it may require further clinical studies in the near future, the current study opens up the possibilities for the use of the metalloproteinase inhibitor, BB-94, in the treatment of multiple organ hemorrhagic injuries in DJES. "
03/01/2010 - "This study examined the effect that the broad-spectrum MMP inhibitor BB-94 has when applied topically to full-thickness skin excisional wounds in rats and its ability to inhibit the promotion of myofibroblast formation and function by the latent transforming-growth factor-beta1 (TGF-beta1). "
12/15/2015 - "Then, we tested the effect of metalloproteinase inhibitor batimastat (BB-94) on TE-induced hemorrhagic injuries in DJES models. "
03/01/2010 - "The increased levels of active MMP-9 may eventually overcome the ability of BB-94 to inhibit this MMP and may explain why wound contraction and other associated events of wound healing were only delayed and not completely inhibited. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
06/15/1999 - "The previously described salutary effects of MMP blockade in mice implanted with pancreatic cancer can be explained in vitro by a dose-dependent diminution of MMP-2 activity and activation in PANC cells exposed to BB-94."
06/15/1999 - "We have shown previously that the metalloproteinase inhibitor, BB-94, prolongs survival and attenuates MMP-2 activity in a murine model of pancreatic cancer. "
05/01/1997 - "The effect of MMP inhibition was determined using the MMP inhibitor BB-94 and a moderately differentiated pancreatic cancer cell line (HPAC). "
05/01/2000 - "To investigate the effect of a matrix metalloproteinase (MMP) inhibitor, BB-94, on the viability, invasion, and metastases of pancreatic cancer. "
05/01/1997 - "In vivo, using an established orthotopic model for pancreatic cancer (LD100 = 80 days), 22 nude mice with orthotopic tumors (30 were implanted) received either BB-94 or vehicle beginning 4 days prior to implantation and continuing to death or sacrifice on Day 70. "
01/01/2014 - "Mice that received BB-94 presented significantly diminished MMP-9 levels (p < 0.01), intracerebral bleeding (p < 0.01), and blood-brain barrier (BBB) breakdown (p < 0.05) in comparison with untreated animals. "
04/01/2008 - "Unexpectedly, the broad-spectrum MMP inhibitor BB-94 increased hemorrhage size and TUNEL-labeled cells. "
03/01/2002 - "Rats treated with BB-94 and tPA showed significantly reduced hemorrhage volumes compared with those that received tPA alone. "
12/01/2000 - "However, when the combination of BB-94 and tPA was administered to rabbits, there was only a 41% incidence of hemorrhage (compared with 77% in the tPA group; P:<0. "
12/01/2000 - "The rabbits treated with BB-94 had an 18% incidence of hemorrhage (P:>0.05 compared with control). "
02/01/2003 - "Animals in the BB-94 group had decreased amylase levels (1086.0 +/- 61.7 U/L vs 2232.7 +/- 309.9 U/L; P < 0.05), decreased cellular infiltrate (1.4 +/- 0.2 vs 2.3 +/- 0.2; P < 0.02), and decreased necrosis (4.1 +/- 0.3 vs 6.1 +/- 0.4; P < 0.005) compared to the control group. "
11/01/2001 - "In a mouse model of lethal hepatitis induced by TNF, apoptosis and necrosis of hepatocytes, but also lethality, hypothermia and influx of leukocytes into the liver, are prevented by a broad-spectrum matrix metalloproteinase (MMP) inhibitor, BB-94. "
07/01/2010 - "Chronic administration of batimastat (BB-94), a broad spectrum peptide inhibitor of MMPs, reduced necrosis, infiltration of macrophages, centronucleated fibers, and the expression of embryonic myosin heavy chain in skeletal muscle of mdx mice. "
12/15/2015 - "In addition, being consistent with the imaging results, histopathological and terminal deoxynucleotidyl transferase-mediated UTP end labeling (TUNEL)-like staining observations also clearly corroborated this hypothesis, as BB-94 was highly effective in neutralizing TE-induced extensive hemorrhage and necrosis in DJES rat model. "
03/01/2004 - "Hmeprin is inhibited by hydroxamic acid derivatives such as batimastat, galardin and Pro-Leu-Gly-hydroxamate, by TAPI-0 (tumour necrosis factor alpha protease inhibitor-0) and TAPI-2, and by thiol-based compounds such as captopril. "
|1.||batimastat (BB 94)
|7.||glucuronyl glucosamine glycan sulfate (Vessel)
|8.||Uridine Triphosphate (UTP)
|9.||DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
|1.||Heterologous Transplantation (Xenotransplantation)